Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Those Chemistry Bloggers | Main | So, How Well Does Winning a Nobel Set You Up? »

October 18, 2010

Merck vs. J&J: Wait For It

Email This Entry

Posted by Derek

We're going to have to wait to find out of the whole Schering-Plough-buys-Merck charade is really going to allow revenue from J&J's Remicade to stay with the merged company. That merged company is known as "Merck", of course, and is run by Merck people from Merck's headquarters, so it's going to be interesting to see how that dispute goes. But although the first arguments have been made before an arbitration board, the decision doesn't look to be made until sometime next year. It sounds as if Merck is already trying to lower expectations, though. . .

Comments (4) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. ty on October 18, 2010 9:38 AM writes...

I couldn't find a reference to the "lower expectations" but I'm pretty sure there's a finance/accounting principle that for SEC traded securities, you are required to lean towards the conservative side for financial projections. This may be an oversimplification, but when litigations are ongoing, firms are required to assume (on their books to varying degrees) that they will lose.

Permalink to Comment

2. Tony on October 18, 2010 4:41 PM writes...

I hope they get burned on this one. Merck used to be a great company and they they pretty much suck. Following the Pfizer model which hasn't raised their stock and will not help Merck either.

Permalink to Comment

3. betalactam on October 18, 2010 7:05 PM writes...

I thought the new company was called Shmerck?

Permalink to Comment

4. Tony on November 6, 2010 6:09 PM writes...

I heard that Derek interviewed at both Merck and J&J and thats how he got the scoop on this article. Anyone know if thats true ?

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
How Not to Do It: NMR Magnets
Allergan Escapes Valeant
Vytorin Actually Works
Fatalities at DuPont
The New York TImes on Drug Discovery
How Are Things at Princeton?
Phage-Derived Catalysts
Our Most Snorted-At Papers This Month. . .